Draft:Martin Kolb
Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit or make changes to this draft, simply click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about either yourself or your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Nnds1996 (talk | contribs) 5 months ago. (Update) |
Martin Kolb | |
|---|---|
| Born | May 21, 1964 Schweinfurt, Germany |
| Awards | American Thoracic Society, Fellow, (2025)
Canadian Academy of Health Sciences, Fellow, (2024) European Respiratory Society, Presidential Honorary Membership, (2022) St. Joseph's Healthcare Hamilton, Anne & Neil McArthur Research Award, (2021) Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Diseases (2021) Moran Campbell Chair in Respiratory Medicine (2016-2021) |
| Academic background | |
| Education | Julius-Maximillian University Wϋrzburg (M.D.) Julius-Maximillian University Wϋrzburg (PhD.) |
Academic advisor | Jack Gauldie |
| Academic work | |
| Discipline | Medicine |
Sub-discipline | Immunology, Respiratory Diseases |
Dr. Martin Rainer Josef Kolb (born May 21, 1964) a German-Canadian Respirologist who is the inaugural holder of the Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Diseases[1] and previous holder of the Moran Campbell Chair in Respiratory Medicine, two endowed chairs at McMaster University. He is currently the Research Director of the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton and a Professor in the Department of Pathology and Molecular Medicine and Director of Respiratory at McMaster University.[2]
Biography
Education
Dr. Kolb graduated from Medical School at Julius-Maximillian University Wϋrzburg in 1992, where he went on to also complete his residency in internal medicine from 1993-1999. During this time, he also completed his residency training in clinical and anatomical pathology at the University of Erlangen–Nuremberg. Following a meeting with internationally renowned Canadian immunologist, Dr. Jack Gauldie, he was invited to complete a post-doctoral research fellowship in molecular medicine at McMaster University, under his mentorship.[1] Following this, Dr. Kolb received the academic title of Privatdozent, a doctoral academic designation, from his alma mater in 2003.[3]
Teaching and professional experience
Dr. Kolb is Tenured Professor of Medicine at McMaster University, where he also served as Director of the Division of Respirology from 2013-2024[4]. He is Research Director at the Firestone Institute for Respiratory Health, a globally recognized center for respiratory research and care. In 2015, Dr. Kolb cofounded the Canadian Registry for Pulmonary Fibrosis, a multi-center registry designed to study the natural history of fibrotic interstitial lung disease in adults, of which he is the co-Director.[5]
Professional contributions
Research and development
Dr. Kolb’s is most well known for his research into the key mechanisms and treatable pathways in idiopathic pulmonary fibrosis and pulmonary hypertension associated with interstitial lung disease, including gene expression, signaling pathways, and progenitor cell biology. He has been a part of many pivotal international clinical trials, across 30 countries, have been conducted, with a focus on biomarkers and novel therapeutics for idiopathic pulmonary fibrosis.[1] He has assisted in the development and evaluation of the now standardized use of the antifibrotic drugs Nintedanib and Pirfenidone for this disease[6]. This was the first effective treatment of available for patients with idiopathic pulmonary fibrosis[7].
Editorial work
Dr. Kolb was the Chief Editor for the European Respiratory Journal from 2018 to 2022. Under his tenure, during the COVID-19 pandemic that gave way to an unprecedented volume of respirology submissions across medical journals, the journal’s impact factor rose from 12 to 34[2]. He has authored over 300 peer-reviewed publications, review articles, and editorials, in leading journals such as the European Respiratory Journal, The New England Journal of Medicine, Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine and The American Journal of Pathology. Over the course of his career, he has collectively garnered over 30,000 citations, earning him an H-index of 87.[8]
Notable awards and Honors
Dr. Kolb is the inaugural holder of the Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Diseases, named after his mentor. He previously held the Moran Campbell Chair in Respiratory Medicine.[1]
In 2011, He was the recipient of the Excellence Award in Integrated Traditional and Western Medicine from the Beijing University of Chinese Medicine and State Administration of Foreign Experts Affairs, China. Dr. Kolb was awarded the Anne and Neil McArthur Research Award from St. Joseph’s Healthcare Hamilton in 2021.[9] He received a Presidential Honorary Membership with the European Respiratory Society in 2022.[10]
He was inducted as a Fellow of the Canadian Academy of Health Sciences in 2024[4] and the American Thoracic Society in 2025.[11]
References
- ^ a b c d "Lung disease specialist takes up chair named for mentor". McMaster University - Faculty of Health Sciences. 2021-05-17.
{{cite web}}: CS1 maint: date and year (link) - ^ a b Grossi, Giuliana (2025-12-11). "Martin Kolb, MD, PhD, on Phase 2b Trial for Idiopathic Pulmonary Fibrosis Treatment | HCPLive". www.hcplive.com. Retrieved 2025-12-11.
- ^ "Martin Kolb". fondazione-menarini.com. Retrieved 2025-12-11.
- ^ a b "Dr. Martin Kolb Elected as Fellow of the Canadian Academy of Health Sciences | News". The Research Institute of St. Joe's Hamilton. Retrieved 2025-12-11.
- ^ "About the Registry – CARE-PF". Retrieved 2025-12-11.
- ^ Raghu, Ganesh; Rochwerg, Bram; Zhang, Yuan; Garcia, Carlos A. Cuello; Azuma, Arata; Behr, Juergen; Brozek, Jan L.; Collard, Harold R.; Cunningham, William; Homma, Sakae; Johkoh, Takeshi; Martinez, Fernando J.; Myers, Jeffrey; Protzko, Shandra L.; Richeldi, Luca (2015-07-15). "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline". American Journal of Respiratory and Critical Care Medicine. 192 (2): e3–e19. doi:10.1164/rccm.201506-1063ST. ISSN 1073-449X.
- ^ "Health System News Mother of Four Has Hope Living with Lung Disease Thanks to New Research". www.oha.com. Retrieved 2025-12-11.
- ^ "Martin Kolb". scholar.google.com. Retrieved 2025-12-11.
- ^ "Wayback Machine" (PDF). medicine.healthsci.mcmaster.ca. Archived from the original (PDF) on 2024-12-09. Retrieved 2025-12-12.
{{cite web}}: Cite uses generic title (help) - ^ Watson, Peter (2022-08-11). "ERS 2022 award winners announced ahead of Congress". ERS - European Respiratory Society. Retrieved 2025-12-12.
- ^ "American Thoracic Society | ATS Fellows List". American Thoracic Society. Retrieved 2025-12-11.
External links
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.

